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Background/Objectives: Protein concentration is lower in human milk (HM) than in infant formula. The objective of this study
was to evaluate the effect of an a-lactalbumin-enriched formula with a lower protein concentration on infant growth, protein
markers and biochemistries.
Subjects/Methods: Healthy term formula-fed (FF) infants 5–14 days old were randomized in this controlled, double-blind trial
to standard formula (SF: 14.1g/l protein, 662kcal/l) group (n¼112) or experimental formula (EF: 12.8g/l protein, 662kcal/l)
group (n¼112) for 120 days; a HM reference group (n¼112) was included. Primary outcome was weight gain (g/day) from
D0 to D120. Secondary outcomes included serum albumin, plasma amino acids insulin and incidence of study events.
Anthropometric measures were expressed as Z-scores using 2006 World Health Organization growth standards.
Results: A total of 321 of the 336 infants (96%) who enrolled, completed the study. Mean age was 9.6 (±2.9) days; 50% were
girls. Mean weight gain (g/day) did not significantly differ between SF vs EF (P¼0.67) nor between EF vs HM (P¼0.11);
however weight gain (g/day) was significantly greater in the SF vs HM group (P¼0.04). At day 120, mean weight-for-age
Z-score (WAZ) and weight-for-length Z-score (WLZ) did not significantly differ between SF vs EF nor EF vs HM; however the WAZ
was significantly greater in SF vs HM (P¼0.025). Secondary outcomes were within normal ranges for all groups. Incidence of
study events did not differ among groups.
Conclusions: a-Lactalbumin-enriched formula containing12.8g/l protein was safe and supported age-appropriate growth;
weight gain with EF was intermediate between SF and HM groups and resulted in growth similar to HM-fed infants in terms of
weight gain, WAZ and WLZ.
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Introduction
Human milk (HM) is the gold standard of early infant
nutrition. The World Health Organization (World Health
Organization, 2003) and the American Academy of Pediatrics
(Koosha et al., 2008; CON AAP, 2009) recommend that
infants be exclusively breastfed for the first 6 months of life.
However, this recommendation is not consistently achieved;
reported rates of exclusive breast feeding at 6 months of age
range from 10 to 46% (World Health Organization, 2003;
Koosha et al., 2008). The World Health Organization
and AAP recognize infant formula as a suitable feeding
alternative when HM is not available (World Health
Organization, 2003; CON AAP, 2009). Mixed feeding
(breastfed and infant formula) does occur, and it is estimated
that between 35 and 50% of the infants receive some
feedings of infant formula during the first 6 months of life
(Bolling et al., 2007; Shealy et al., 2008). Given the number of
infants receiving mixed feedings (HM and formula), and the
importance of early life nutrition for optimal growth and
development, continued research related to the composition
of infant formula and health outcomes of formula fed (FF)
infants is warranted.
One of the areas in which HM and infant formula differ is
in protein composition and concentration. Mature HM
provides 10–12gm/l total protein (Lonnerdal et al., 1976;
Raiha et al., 1986; Darragh and Moughan, 1998; Feng et al.,
2009) and is rich in essential amino acids. Standard infant
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higher total protein concentration and contains a different
amino acid profile than HM. A higher total protein
concentration in infant formula (14–15gm/l) has been
necessary to provide sufficient quantities of all the essential
amino acids.
Higher protein concentration in infant formula is
hypothesized to be a factor that contributes to growth
differences observed between FF- and HM-fed infants
(Koletzko et al., 2009). FF infants tend to have higher post
prandial (Tikanoja and Simell, 1983) and fasting (Picone
et al., 1989; Hanning et al., 1992; Akeson et al., 1998)
concentrations of branched chain amino acids compared
with HM-fed infants. Plasma concentrations of these amino
acids have been positively correlated with insulin release
(Ginsburg et al., 1984), and insulin is known to increase
cellular glucose uptake and inhibit lypolysis. These
metabolic alterations are proposed mechanisms for greater
weight gain and greater weight-for-length z-scores (WLZ) or
body mass index in FF infants compared with HM-fed infants
(Lucas et al., 1980). Rapid weight gain, upward crossing
of growth percentiles and a greater weight-for-length at
6 months have been identified as risk factors for over-
weight and obesity, later in life (Stettler et al., 2002, 2003;
Karaolis-Danckert et al., 2007; Taveras et al., 2009).
The primary limiting factor in reducing the total protein
concentration in infant formula is the ability to provide
sufficient quantities of essential amino acids. This can,
in part, be addressed by enriching whey protein fractions
in formula with substantially higher concentrations of
a-lactalbumin; a-lactalbumin is the predominant whey
protein found in HM and is a rich source of essential amino
acids (Lien et al., 2004). a-Lactalbumin accounts for 28% of
the total protein in HM and only 3% of the total protein
in bovine milk (Heine et al., 1991). Human and bovine
a-lactalbumin share 72% amino acid sequence homology
and both consist of 123 amino acids (Findlay and Brew,
1972). Infants fed a formula enriched with bovine
a-lactalbumin (14g/l protein, 2.2g/l a-lactalbumin) demon-
strated appropriate growth and biomarkers of protein status
(Lien et al., 2004), as well as good gastrointestinal tolerance
to the formula (Davis et al., 2008). It was notable that the
plasma amino acid concentrations in the infants consuming
the 14g/l protein formula were similar to but slightly higher
than those fed HM (Davis et al., 2008). These data suggested
that a further reduction in protein concentration of an
a-lactalbumin-enriched formula might be achievable, while
still supporting appropriate growth.
This study sought to evaluate the safety and efficacy of a
new, lower protein, a-lactalbumin-enriched formula. The
primary hypothesis was that weight gain of infants fed this
lower protein experimental formula (EF) would be less than
but within 3g/day of those fed the higher protein standard
formula (SF), which in addition to other parameters, would
indicate that the lower protein concentration was indeed
suitable for term infants. We also sought to evaluate whether
the modest reduction in the formula’s total protein con-
centration would result in growth outcomes in EF infants
that were similar to HM-fed infants.
Subjects and methods
Study design
This study was a randomized, controlled, double-blind study
of healthy term FF infants; FF infants were randomized to
receive either SF or EF, and a HM group was included as a
reference. The protocol and informed consent form were
reviewed and approved by the National Ethics Committee
and the Bureau of Food and Drugs in the Philippines.
Written informed consent was obtained from the parent or
legal guardian of each infant before enrollment.
Subjects
Inclusion criteria required that infants were at birth, a
singleton and term infant; at enrollment were 5–14 days of
age, and had a weight, length and head circumference Xfifth
and pninety-fifth percentile for age according to Filipino
growth reference standards (Florentino et al., 1992), and
exclusively consuming and tolerating a cow’s milk
infant formula (to be eligible for FF group), or exclusively
consuming and tolerating HM (to be eligible for HM group).
Main exclusion criteria included: a family history of allergy
to a cow’s milk protein formula, major congenital malforma-
tions, infection or other systemic disorders.
Methods
Randomization. Allocation of FF infants to one of the two
study formulas proceeded through the use of a gender-
stratified randomization schedule. To ensure double blind-
ing, the packaging of the study formula was identical aside
from the package number. Formula feeding began after
randomization (baseline) and continued for 120 days.
Nutrient composition of study formulas. Study formulas,
standard S-26 GOLD (SF) or experimental S-26 GOLD (EF)
(Wyeth Nutrition, Askeaton, Ireland) were packaged in
250ml ready-to-feed Tetra Brik cartons (Tetra Pak, Lund,
Sweden). The main difference between the formulas (Table 1)
was the total protein concentration. The ability to provide
the required amount of essential amino acids in a formula
with a lower protein concentration was achieved primarily
through enrichment of the formula with a-lactalbumin and
supplementation with small amounts of L-tyrosine and L-
tryptophan. The vitamin and mineral concentrations of the
study formulas were similar. Both formulas satisfied the
essential composition requirements of Codex and EU
Commissions (Codex Alimentarius Commission, 1981;
European Commission, 2006) and the US Infant Formula
Act (United States Food and Drug Administration, 2004).
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head circumference were measured at baseline, days 30, 60,
90 and 120. Weight of naked infants was measured on an
infant scale (Seca 374, Hamburg, Germany), recumbent
length was measured on a pediatric length board (Ellard
Instrumentation, Washington, DC, USA) and head circum-
ference was measured utilizing a pediatric tape measure (Seca
212, Hamburg, Germany). All anthropometric measures were
taken twice at each visit and the mean was calculated.
Serum/plasma biochemistries. Blood samples were collected
at baseline, study days 60 and 120. At day 60, a timed blood
sample (2h post-prandial) was collected to assess plasma
essential and conditionally essential amino acids, insulin and
glucose concentrations. Serum chemistries were analyzed by
spectrophotometry, serum insulin was measured by radio-
immunoassay and serum glucose was measured by spectro-
photometry (Quest Diagnostics Clinical Trials, Valencia, CA,
USA). Plasma amino acids were analyzed by ion-exchange
chromatography with the exception of tryptophan, which was
analyzed by tandem liquid chromatography mass spectro-
scopy (Mayo Clinical Trial Services, Rochester, MN, USA).
Study events. Study events were recorded throughout the
study. A study event was defined as any untoward, undesired
or unplanned event in the form of signs, symptoms, disease
or laboratory or physiological observations occurring in a
person given a test article (study formula) or enrolled in the
study. The investigator assigned each event as ‘related’ if
there was a reasonable causal relationship to the test article,
or ‘not related’ if there was not a reasonable causal relation-
ship to the test article. A subset of symptoms related to the
digestive system and gastrointestinal tolerance were identi-
fied of particular interest a priori: hard stool, constipation,
difficulty having a bowel movement, acute diarrhea, chronic
diarrhea, spitting up, regurgitation, vomiting, gastroesopha-
geal reflux disease, colic and crying/neonatal abnormal
crying. To ensure consistency in diagnosis, investigators
were provided with standard definitions for these symptoms.
Data management. Data management was performed by
Accenture (Philadelphia, PA, USA). Remote data capture was
used to electronically record data; study monitors verified
data in RDC against the source data and identified and
resolved discrepancies. Data collection, data entry, query
process, data review and database lock were performed
according to standard operating procedures.
Statistical analysis. Data analysis was conducted as outlined
in the statistical analysis plan utilizing SAS software version
9.1.3 (Cary, NC, USA). Analysis populations were defined as
follows, intent to treat: subjects with a randomization
number and efficacy analyzable: all randomized infants
who took at least one feed of the study formula and have a
measurable primary endpoint. Anthropometric measures
were evaluated as raw data and also expressed as z-scores
relative to the growth standards of the World Health
Organization (WHO Multicentre Growth Reference 2006)
using a World Health Organization software program (http://
www.who.int/childgrowth/software/en/). Baseline z-score
Table 1 Macronutrient composition of study formulas
a
SF EF Recommendations
b
Codex alimentarus EU commission
Min Max Min Max
Energy, kcal/l 672 666 600 700 600 700
Protein: energy ratio, g protein per 100kcal 2.1 1.9 1.8 3.0 1.8 3.0
Protein, g/l 14.1 12.8 See above See above
Histidine, mg/100kcal 51 45 40 41
Isoleucine 113 103 90 92
Leucine 205 186 166 169
Lysine 182 170 113 114
Threonine 122 110 77 77
Tryptophan 36 37 32 33
Methionine þ cysteine
c 84 76 61 62
Tyrosine þ phenylalanine
d 176 170 159 156
a-Lactalbumin, g/l 2.2 2.3 No recommendations No recommendations
Whey:casein 60:40 66:34 No recommendations No recommendations
Carbohydrate, g/100kcal 10.8 10.8 9.0 14.0 9.0 14.0
Fat, g/100kcal 5.4 5.4 4.4 6.0 4.4 6.0
Abbreviations: EF, experimental formula; EU, European union; Min, minimum; Max, maximum; SF, standard formula.
aNutrient composition analyzed by Covance Laboratories, Madison, WI, USA; total protein calculated as total nitrogen  6.25.
bCodex and EU recommendations for infant formula composition are based on a compilation of published literature values on human milk composition.
cThe concentration of methionine and cystine/cysteine may be added together if the ratio between methionine and cystine is not greater than 2.
dThe concentration of tyrosine and phenylalanine may be added together if the ratio between tyrosine:phenylalanine is not greater than 2.
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means based on an ANCOVA with baseline and feeding
group in the model.
Comparison between the EF and SF groups was of interest,
as was the comparisons between each formula group and the
HM group. Analyses were conducted as independent sets of
pairwise comparisons because the HM group was included as
a reference group and was not a randomized group. A sample
size of 90 subjects per arm (45 subjects per gender per arm)
was required to have 80% power to detect a difference in
weight gain of 3g/day (baseline to day 120) between groups,
when testing at an a level of 0.025 (one-tailed). The error rate
was held constant at the a¼0.05 level for all outcomes.
Given the multiple t-tests performed for the plasma essential
amino acid analysis, results are also present using the
Bonferroni adjustment for multiplicity aadj¼0.0015.
Results
Subject disposition, study events and subject demography
Of the 336 infants enrolled (112 infants per group), 321
infants completed the study (96%). The number of disconti-
nuations for study events was low and not significantly
different between groups (2.7, 2.7 and 0% in the SF, EF and
HM groups, respectively). The primary safety endpoint was
the frequency of study events; study events were distributed
across all treatment groups. A total of 25 treatment-related
gastrointestinal (GI) study events occurred (see Methods):
6.3% in the EF group, 11.6% in the SF group and 4.5% in the
HM group. Baseline infant characteristics were comparable
between the groups (Table 2), with the exception of birth
weight, which was significantly higher in the formula groups
compared with HM (P¼0.005, HM vs EF or SF). Mothers of
FF infants gained significantly (P¼0.014) more weight
during pregnancy compared with mothers of HM-fed infants
(EF: 11.8kg, SF: 11.2kg and HM: 10.2kg).
Growth velocity
Mean weight gain (baseline to day 120g/day) did not
significantly differ between neither EF vs SF (P¼0.67) nor
EF vs HM (P¼0.11); however, weight gain was significantly
greater in the SF vs HM group (P¼0.04) (Table 3). Mean
length gain (baseline to day 120) was comparable and did
not significantly differ between EF vs SF. Mean length gain of
the EF group was slightly greater than that of the HM infants
(P¼0.03).
Z-scores
At baseline, there were no significant differences between
the EF and SF groups in weight-for-age z-score (WAZ), length-
for-age z-score, head circumference-for-age z-score or WLZ
(Figure 1). Both formula groups were significantly higher
than HM group at baseline for WAZ (P¼0.008 and P¼0.012
for EF and SF, respectively) and head circumference-for-age
z-score (P¼0.03 and P¼0.003 for EF and SF, respectively).
The mean WLZ of SF group was significantly higher than the
HM group (P¼0.03) at baseline.
At day 120, there were no significant differences between
the EF and SF groups for any mean z-score parameters
(adjusted for baseline). The adjusted mean WAZ of the SF
group was significantly higher than the HM group (mean
difference 0.245, P¼0.03). The adjusted mean length-for-age
z-score of the EF and SF groups were significantly higher than
the HM group (mean difference 0.269 and 0.243, P¼0.001
and P¼0.002, for EF and SF groups, respectively). The
adjusted mean head circumference-for-age z-score of the
EF and SF groups were significantly higher than HM (mean
difference 0.227 and 0.219, P¼0.007 and P¼0.009 for EF
and SF groups, respectively). There was no significant
difference in the adjusted mean WLZ for either formula
group against HM at study day 120.
Serum biochemistries and amino acids
Mean concentrations of serum albumin, total protein, blood
urea nitrogen and creatinine were within the normal range Table 2 Subject demography by feeding group
a
SF
(n¼112)
EF
(n¼112)
HM
(n¼112)
Gestational age (weeks) 38.5 (0.9) 38.6 (0.8) 38.6 (0.9)
Birth weight (kg) 3.14 (0.42)
b 3.17 (0.43)
c 3.00 (0.40)
Birth length (cm) 49.4 (2.0) 49.5 (2.0) 49.4 (1.7)
Age at enrollment (days) 9.5 (3.0) 9.5 (2.7) 9.8 (3.0)
Gender (% male) 50 50 50
Race (% Asian) 100 100 100
Abbreviations: HM, human milk; EF, experimental formula; SF, standard
formula; values presented are means (s.d.).
aIntent-to-treat (ITT)population.
bSignificant difference between SF vs HM, Po0.05 (P-value based on
two-sample t-test).
cSignificant difference between EF vs HM, Po0.05 (P-value based on
two-sample t-test).
Differences observed for both ITT population (data shown in table) and
efficacy analyzable population (data not shown).
Table 3 Growth velocity by feeding group
a
SF
(n¼108)
EF
(n¼103)
HM
(n¼110)
Weight gain, g/day 28.1 (5.4)
b 27.8 (5.3) 26.6 (5.4)
Length gain, cm/month 3.21 (0.33) 3.22 (0.35)
c 3.12 (0.32)
Head circumference,
cm/month
1.60 (0.20) 1.61 (0.22)
c 1.55 (0.18)
Abbreviations: HM, human milk; EF, experimental formula; SF, standard
formula; values presented are means (s.d.).
aEfficacy analyzable population; growth velocity ¼ rate of change from
baseline to day 120.
bSignificant difference between SF vs HM group, Po0.05 (P-value based on
two-sample t-test).
cSignificant difference between EF vs HM group, Po0.05 (P-value based on
two-sample t-test).
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tions of glucose and insulin did not differ between groups.
There were no significant differences in the mean amino acid
concentrations between the EF and SF groups (Table 5). EF
and SF infants had a significantly greater concentrations of
some amino acids (lysine, methionine, phenylalanine and
threonine) compared with the HM group, however, the
mean concentrations of these amino acids were within the
normal range for all groups. In general, the plasma essential
amino acid concentrations of both the EF and SF formula
groups were similar to and within one s.d. of the HM group.
Discussion
This study demonstrated that healthy term infants fed a new
lower protein formula (EF) had an age-appropriate growth,
biomarkers of protein status and biochemistries were
normal, and no difference in the incidence of study events
compared with the SF and HM groups. Weight gain with the
new lower protein formula (EF) was intermediate between SF
and HM groups; infants who consumed the new formula had
weight gain, WAZ and WLZ similar to the HM-fed infant.
This study compared growth of infants fed formulas that had
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Figure 1 Z-scores are based on the World Health Organization reference data (World Health Organization, 2003). (a) weight-for-age Z-score,
(b) length-for-age Z-score, (c) head circumference-for age-Z-score, (d) weight-for-length Z-score. Baseline values are means; P-values are based
on a two-sample t-test. Study day values are least square (LS) means (study day mean adjusted for baseline); P-value is based on ANCOVA with
baseline value and feeding group in the model. Significance declared at Po0.05; **Significant difference between SF and HM groups;
*Significant difference between EF and HM groups.
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both formulas were found to be safe and support growth, but
notably the weight gain in the lower protein (EF) group was
not significantly different from the HM group.
Evidence of a positive relationship between the protein
concentration of feeding and weight gain is hypothesized
(Koletzko et al., 2009), and supported by the results of
randomized and observational studies. In prospective rando-
mized trials, infants receiving a higher protein formula have
been shown to have greater weight gain (Raiha et al., 1986;
Axelsson et al., 1989) or greater WAZ (Koletzko et al., 2009)
compared with infants receiving a lower protein formula.
Randomized trials that have not found this difference
(Janas et al., 1987; Picone et al., 1989; Turck et al., 2006)
tended to have a smaller difference in protein concentration
between the formulas as well as a smaller sample size. In
observational cohort studies, a higher protein intake
(Gunnarsdottir and Thorsdottir, 2003) and a higher percen-
tage of dietary energy as protein (Rolland-Cachera et al.,
1995; Scaglioni et al., 2000) have been associated with
overweight or increased body mass index at an age of 5–8
years, and an association between weight gain in infancy and
later life obesity has also been shown (Stettler et al., 2002;
Ong et al., 2009). In summary, the literature suggests that the
protein concentration of infant feeding has a role in weight
gain during infancy, which in turn may have effect on
weight in later life; this underscores the importance of the
results of weight gain observed in the lower protein (EF)
group in this study.
The difference in weight gain between the EF and SF
groups was 0.3g/day and although this represents only a
modest reduction on a daily basis, it is cumulative and may
be meaningful when projected over a longer time period.
Indeed, at the conclusion of the study the mean adjusted
WAZ of infants fed EF was not significantly different from
that of HM group, whereas those receiving the SF had
significantly greater WAZ compared with that of HM group.
Both the formula groups had a significantly greater rate of
length gain and length-for-age Z-scores compared with that
of the HM group. Although the formula groups were longer
than their HM-fed counterparts, their weight was propor-
tional to their length as demonstrated by no significant
difference in the WLZ of either of the formula group against
the HM group at the conclusion of the study.
The plasma essential and conditional amino acid concen-
trations of infants fed with EF were for the most part
intermediate between the SF and HM groups. Higher
concentrations of the branched chain amino acids leucine,
isoleucine and valine have been positively correlated with
insulin concentrations (Ginsburg et al., 1984), which in turn
may affect weight gain. This study found no significant
difference in insulin concentrations between any of the
groups. Higher insulin concentration in FF infants compared
with HM-fed infants found in an earlier study (Lucas et al.,
1980) may be because of substantially higher total protein
concentration of infant formulas at that time.
Table 4 Serum biochemistries by feeding group
a
Units SF
(n¼108)
EF
(n¼103)
HM
(n¼110)
Albumin
Baseline g/l 40.0 (3.0) 40.9 (2.5) 40.5 (2.8)
Day 60 42.7 (2.2) 42.6 (2.2) 42.3 (2.3)
Day 120 44.5 (2.2) 45.0 (2.3)
b 44.0 (2.1)
Total protein
Baseline g/l 61.4 (4.6) 61.9 (4.4) 61.3 (4.5)
Day 60 61.4 (4.3) 60.8 (6.3) 61.2 (3.6)
Day 120 63.8 (4.0) 64.1 (4.2) 63.9 (4.2)
BUN
Baseline mg per 100ml 8.4 (2.9) 8.4 (2.3) 8.8 (2.8)
Day 60 6.7 (1.3)
c 5.7 (1.4) 5.3 (1.8)
c
Day 120 6.9 (1.8)
c 6.4 (1.8)
b 4.8 (1.4)
b,c
Creatinine
Baseline mmol/l 42.5 (9.5) 41.7 (9.3) 41.1 (8.1)
Day 60 26.8 (3.3) 26.5 (3.5) 27.1 (2.2)
Day 120 27.3 (3.2) 26.9 (3.6) 27.3 (2.3)
Insulin
Day 60 mU/ml 6.48 (4.18) 7.35 (4.83) 6.58 (4.47)
Glucose
Day 60 mg per 100ml 67.9 (10.1) 68.1 (10.2) 70.2 (8.84)
Abbreviations: BUN, blood urea nitrogen; HM, human milk; EF, experimental
formula; SF, standard formula; values presented are means (s.d.).
aEfficacy analyzable population.
bSignificant difference between EF vs HM, Po0.05 (P-value based on
two-sample t-test).
cSignificant difference between SF vs HM, Po0.05 (P-value based on
two-sample t-test).
Table 5 Mean plasma essential amino acid concentrations by feeding
group
a
SF
(n¼108)
EF
(n¼103)
HM
(n¼110)
Cystine, mmol/l 13.67 (7.24) 13.80 (6.27) 12.47 (5.73)
Histidine 85.36 (12.02)
b 84.45 (12.89) 81.86 (9.61)
Isoleucine 60.80 (2.64)
b,c 58.66 (13.86)
d 53.45 (12.52)
Leucine 105.24 (19.37) 101.59 (21.77) 104.23 (20.72)
Lysine 193.74 (33.74)
b,c 192.52 (39.71)
d,e 169.93 (35.08)
Methionine 33.73 (7.77)
b,c 33.49 (6.76)
d,e 29.99 (5.86)
Phenylalanine 54.47 (8.06)
b,c 52.83 (8.99)
d,e 48.57 (9.65)
Threonine 182.11 (44.02)
b,c 183.65 (40.84)
d,e 132.50 (29.42)
Tryptophan 62.79 (13.13) 64.78 (11.78)
d 60.89 (11.73)
Tyrosine 79.86 (15.87) 88.31 (21.48)
d,e 77.95 (15.11)
Valine 166.17 (27.44)
b,c 154.26 (29.52)
d 143.75 (31.93)
Abbreviations: HM, human milk; EF, experimental formula; SF, standard
formula; values presented are means (s.d.).
aEfficacy analyzable population.
bSignificant difference between SF vs HM, Po0.05 (P-value based on
two-sample t-test).
cSignificant difference between SF vs HM adjusted for multiplicity, Po0.0015
(P-value based on two-sample t-test).
dSignificant difference between EF vs HM, Po0.05 (P-value based on
two-sample t-test).
eSignificant difference between EF vs HM adjusted for multiplicity, Po0.0015
(P-value based on two-sample t-test).
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stratification and completion rate. The completion rate
exceeded the minimum sample size needed to test the
primary hypothesis, and gender balance was achieved within
each group. A limitation of the study relates to the duration
of the clinical trial infants received the study formula until
they were 4.5 months of age. We do not know whether the
weight gain observed in the EF group will have an impact on
weight status in later age.
In summary, a randomized clinical trial demonstrated that
the new lower protein a-lactalbumin-enriched formula (EF)
is appropriate for term infants as evidenced by age-
appropriate growth, markers of protein status, plasma essen-
tial amino acid concentrations and gastrointestinal tolerance.
Infants randomized to the lower protein formula had growth
outcomes similar to HM-fed infants in terms of weight gain,
WAZ and WLZ. These data suggest that a modest reduction in
the total protein concentration of the formula has an effect
on growth in the short term; further studies are needed to
determine if the trend in weight gain observed in the EF group
has an impact on weight status in later life.
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